Stock Events

Stock Events

Opus Genetics 

$4.4
57
-$0.02-0.45% Wednesday 02:45

Statistics

Day High
4.41
Day Low
4.4
52W High
-
52W Low
-
Volume
336
Avg. Volume
-
Mkt Cap
303.44M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

8MayExpected
Q3 2025
Q4 2025
Next
-0.25
-0.2
-0.16
-0.11
Expected EPS
-0.13026
Actual EPS
N/A

Financials

-523.4%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
21.98MRevenue
-115.06MNet Income

Analyst Ratings

$10.57Average Price Target
The highest estimate is 15.00.
From 7 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IRD.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
EyePoint
EYPT
Mkt Cap1.06B
EyePoint Pharmaceuticals focuses on developing treatments for eye diseases, directly competing with Ocuphire's focus on ophthalmic diseases.
Bausch Health Companies
BHC
Mkt Cap2.62B
Bausch Health Companies, through its eye health division, offers products that compete in the broader ophthalmology market.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals offers treatments for eye diseases, including Eylea for macular degeneration, directly competing with Ocuphire's products.
Novartis
NVS
Mkt Cap237.61B
Novartis AG, with its ophthalmology division, competes in developing treatments for eye conditions, including those targeted by Ocuphire.
GSK
GSK
Mkt Cap94.51B
GlaxoSmithKline, through its investments in ophthalmology, competes in the same therapeutic areas as Ocuphire.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie, owning Allergan, an eye care product company, competes in the ophthalmology market, affecting Ocuphire's market share.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a portfolio of ophthalmology treatments, competing with Ocuphire in the eye disease treatment market.
Regenxbio
RGNX
Mkt Cap645.07M
REGENXBIO Inc. focuses on gene therapy for retinal diseases, directly competing with Ocuphire Pharma's focus on eye disorders.

About

Opus Genetics, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. The company offers Phentolamine Ophthalmic Solution for reversal of mydriasis, as well as is in Phase III clinical trials for presbyopia and dim light or night vision disturbances. Its lead retinal product candidate is APX3330, a small-molecule inhibitor of reduction oxidation effector factor-1 protein that has completed Phase II clinical trial for the treatment of diabetic retinopathy. The company also develops APX2009 and APX2014 that are preclinical product candidates for retina indications. The company was formerly known as Ocuphire Pharma, Inc. Opus Genetics, Inc. was founded in 2018 and is headquartered in Farmington Hills, Michigan.
Show more...
CEO
ISIN
US67577R1023

Listings

F
DE
R3X1.F
XNAS
US
IRD
BOATS
BOATS
IRD.BOATS

0 Comments

Share your thoughts

FAQ

What is Opus Genetics stock price today?▼
The current price of IRD.BOATS is $4.4 USD — it has decreased by -0.45% in the past 24 hours. Watch Opus Genetics stock price performance more closely on the chart.
What is Opus Genetics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Opus Genetics stocks are traded under the ticker IRD.BOATS.
What is Opus Genetics market cap?▼
Today Opus Genetics has the market capitalization of 303.44M
When is the next Opus Genetics earnings date?▼
Opus Genetics is going to release the next earnings report on May 08, 2026.
What were Opus Genetics earnings last quarter?▼
IRD.BOATS earnings for the last quarter are -0.19 USD per share, whereas the estimation was -0.11 USD resulting in a -70% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Opus Genetics revenue for the last year?▼
Opus Genetics revenue for the last year amounts to 21.98M USD.
What is Opus Genetics net income for the last year?▼
IRD.BOATS net income for the last year is -115.06M USD.
When did Opus Genetics complete a stock split?▼
Opus Genetics has not had any recent stock splits.